Effect of serum creatinine difference between the Jaffe and the enzymatic method on kidney disease detection and staging

Abstract

Background. Serum creatinine (SCr), mainly determined by the Jaffe or an enzymatic method, is the central marker to assess kidney function. Deviations between these two methods may affect the diagnosis and staging of acute kidney injury (AKI) and chronic kidney disease (CKD). Methods. The results of the first parallel SCr measurement (Jaffe and enzymatic method) of adult in- and outpatients i the same serum sample at the University Hospital Essen (Essen, Germany) between 2020–2022 were retrospectively evaluated. A Bland–Altman plot with 95% limits of agreement (LoAs) was used to assess the difference between the Jaff and the enzymatic SCr (eSCr) method. We used the 2009 Chronic Kidney Disease Epidemiology Collaboration equation for determination of estimated glomerular filtration rate (eGFR) according to the Kidney Disease: Improving Global Outcomes guidelines. Results. A total of 41 144 parallel SCr measurements were evaluated. On average, Jaffe SCr was 0.07 mg/dl higher than eSCr (LoA −0.12; 0.25 mg/dl). In 19% of all cases there was a different CKD stage when comparing eGFR between both SC methods, of which 98% resulted in a more severe CKD stage determined with Jaffe SCr. In 1.6% of all cases Jaffe SCr was ≥0.3 mg/dl higher than eSCr. Conclusion. The present study showed that methods of SCr measurement may affect both the diagnosis and staging o AKI and CKD. This must be taken into account when interpreting measurements of renal function in everyday clinical practice, but also when planning and comparing studies on renal diseases. One should therefore stay with one method for SCr measurement, preferably with the enzymatic method.